The U.S. Food and Drug Administration (FDA) has announced a significant update to the labeling of all extended-release medications used to treat Attention-Deficit ...

Otsuka’s ADHD drug centanafadine is currently under review by the US FDA, with a PDUFA date of 24 July 2026.

The US Food and Drug Administration (FDA) granted marketing approval to California-based NeuroSigma for the first medical device to be indicated for attention deficit hyperactivity disorder (ADHD) ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

Extended-release stimulants are currently not approved for children younger than 6 years, but health care professionals do prescribe them "off label" to treat ADHD. Clinical trials have shown that ...

A large multicenter clinical trial led by King's College London with 150 children and adolescents has shown that a device cleared by the US FDA to treat ADHD is not effective in reducing symptoms. The ...

KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...

ADHD patients deserved a more consistent, safe and manageable medication experience. Imagining a better way forward, they ...

Regardless, the use of an ADHD drug for treating a condition such as binge eating demonstrates one of the most fascinating aspects of medicine: although the biological mechanisms may be the same, ...

The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...